Monday, October 3, 2022


Biotechnology News Magazine

Equifund Successfully Raises Over $1 Million for Biopact CT Via Reg-CF

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Equifund is a private market investment platform that delivers vetted, early-stage investing opportunities. Today they announced they have successfully raised over $1 million for Biopact Cellular Transport Inc. (“Biopact CT”) in a Regulation Crowdfunding offering.

“We’re very proud to have oversubscribed a Reg-CF offering for Biopact CT,” said Jordan Gillissie, Equifund’s Founder and CEO. “We are seeing more and more investors come to our platform looking for high-quality investment opportunities, especially in the biotech and healthcare space. Biopact’s raise was a great success and we’re excited for those who got the chance to participate.”

Biopact CT is a biotech company pioneering a breakthrough technology called MGMR. MGMR is backed by over 110 patents worldwide and could be instrumental in helping cell-based therapies fight many diseases including cancer and diabetes.

“It’s been a great pleasure doing a Reg-CF raise with Equifund,” said Kurt Swogger, CEO of Biopact CT. “From beginning to end, they were great to work with and we’re very happy with the results particularly as we started our fund raising at the “start” of the Pandemic. The Equifund team lead by Jordan adapted and still brought off a successful fund raise. We would definitely consider doing another raise with Equifund in the future.”

Equifund is one of the highest-grossing platforms in the industry on a per offering basis. In the past 18 months it has launched six Reg-CF offerings and generated over $4 million in investor commitments.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine